CA2641308A1 - Utilisation de phosphatase pour traiter des tumeurs surexprimant n-cor - Google Patents

Utilisation de phosphatase pour traiter des tumeurs surexprimant n-cor Download PDF

Info

Publication number: CA2641308A1
Authority: CA; Canada
Prior art keywords: cor; cells; ligand; patient; tumor
Prior art date: 2006-02-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002641308A

Other languages

English (en)

Inventor

Zhengping Zhuang

Edward H. Oldfield

Deric M. Park

Irina Lubensky

Jie Li

John S. Kovach

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Lixte Biotechnology Holdings Inc

US Department of Health and Human Services

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-02-06

Filing date

2007-02-06

Publication date

2007-08-16

2007-02-06 Application filed by Individual filed Critical Individual

2007-08-16 Publication of CA2641308A1 publication Critical patent/CA2641308A1/fr

Status Abandoned legal-status Critical Current

Links

206010028980 Neoplasm Diseases 0.000 title claims abstract description 149
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 title claims abstract description 53
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 title claims abstract description 53
208000005017 glioblastoma Diseases 0.000 claims abstract description 165
239000003446 ligand Substances 0.000 claims abstract description 153
201000010915 Glioblastoma multiforme Diseases 0.000 claims abstract description 150
238000000034 method Methods 0.000 claims abstract description 138
150000001875 compounds Chemical class 0.000 claims abstract description 116
102000003964 Histone deacetylase Human genes 0.000 claims abstract description 66
108090000353 Histone deacetylase Proteins 0.000 claims abstract description 66
102000027483 retinoid hormone receptors Human genes 0.000 claims abstract description 52
108091008679 retinoid hormone receptors Proteins 0.000 claims abstract description 52
239000000203 mixture Substances 0.000 claims abstract description 44
230000002401 inhibitory effect Effects 0.000 claims abstract description 26
230000024245 cell differentiation Effects 0.000 claims abstract description 15
230000001939 inductive effect Effects 0.000 claims abstract description 14
102100022935 Nuclear receptor corepressor 1 Human genes 0.000 claims abstract 92
101710153661 Nuclear receptor corepressor 1 Proteins 0.000 claims abstract 92
210000004027 cell Anatomy 0.000 claims description 165
GXEKYRXVRROBEV-FBXFSONDSA-N (1r,2s,3r,4s)-7-oxabicyclo[2.2.1]heptane-2,3-dicarboxylic acid Chemical compound C1C[C@@H]2[C@@H](C(O)=O)[C@@H](C(=O)O)[C@H]1O2 GXEKYRXVRROBEV-FBXFSONDSA-N 0.000 claims description 77
230000012010 growth Effects 0.000 claims description 73
229930002330 retinoic acid Natural products 0.000 claims description 70
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 69
210000002966 serum Anatomy 0.000 claims description 51
210000000805 cytoplasm Anatomy 0.000 claims description 49
210000004958 brain cell Anatomy 0.000 claims description 41
230000004069 differentiation Effects 0.000 claims description 38
230000001965 increasing effect Effects 0.000 claims description 37
239000003814 drug Substances 0.000 claims description 35
229960001727 tretinoin Drugs 0.000 claims description 35
VEFJHAYOIAAXEU-UHFFFAOYSA-N okadaic acid Natural products CC(CC(O)C1OC2CCC3(CCC(O3)C=CC(C)C4CC(=CC5(OC(CC(C)(O)C(=O)O)CCC5O)O4)C)OC2C(O)C1C)C6OC7(CCCCO7)CCC6C VEFJHAYOIAAXEU-UHFFFAOYSA-N 0.000 claims description 32
QNDVLZJODHBUFM-WFXQOWMNSA-N okadaic acid Chemical compound C([C@H](O1)[C@H](C)/C=C/[C@H]2CC[C@@]3(CC[C@H]4O[C@@H](C([C@@H](O)[C@@H]4O3)=C)[C@@H](O)C[C@H](C)[C@@H]3[C@@H](CC[C@@]4(OCCCC4)O3)C)O2)C(C)=C[C@]21O[C@H](C[C@@](C)(O)C(O)=O)CC[C@H]2O QNDVLZJODHBUFM-WFXQOWMNSA-N 0.000 claims description 32
JAABVEXCGCXWRR-FBXFSONDSA-N rel-norcantharidin Chemical compound C1C[C@H]2[C@@H]3C(=O)OC(=O)[C@@H]3[C@@H]1O2 JAABVEXCGCXWRR-FBXFSONDSA-N 0.000 claims description 30
210000004881 tumor cell Anatomy 0.000 claims description 30
101710193519 Glial fibrillary acidic protein Proteins 0.000 claims description 29
210000005046 glial fibrillary acidic protein Anatomy 0.000 claims description 29
210000001519 tissue Anatomy 0.000 claims description 29
RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 claims description 28
-1 antimonyl tartrate Chemical compound 0.000 claims description 27
206010006187 Breast cancer Diseases 0.000 claims description 26
208000026310 Breast neoplasm Diseases 0.000 claims description 26
SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 claims description 26
210000005260 human cell Anatomy 0.000 claims description 24
229960005280 isotretinoin Drugs 0.000 claims description 24
RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 claims description 23
DHZBEENLJMYSHQ-XCVPVQRUSA-N cantharidin Chemical compound C([C@@H]1O2)C[C@@H]2[C@]2(C)[C@@]1(C)C(=O)OC2=O DHZBEENLJMYSHQ-XCVPVQRUSA-N 0.000 claims description 23
239000003550 marker Substances 0.000 claims description 23
210000001175 cerebrospinal fluid Anatomy 0.000 claims description 22
238000010820 immunofluorescence microscopy Methods 0.000 claims description 18
229940095758 cantharidin Drugs 0.000 claims description 15
229930008397 cantharidin Natural products 0.000 claims description 15
DHZBEENLJMYSHQ-UHFFFAOYSA-N cantharidine Natural products O1C2CCC1C1(C)C2(C)C(=O)OC1=O DHZBEENLJMYSHQ-UHFFFAOYSA-N 0.000 claims description 15
NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims description 15
239000003112 inhibitor Substances 0.000 claims description 15
MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 claims description 15
229960000604 valproic acid Drugs 0.000 claims description 15
206010009944 Colon cancer Diseases 0.000 claims description 13
208000001333 Colorectal Neoplasms Diseases 0.000 claims description 13
206010061535 Ovarian neoplasm Diseases 0.000 claims description 13
230000035755 proliferation Effects 0.000 claims description 13
102100021455 Histone deacetylase 3 Human genes 0.000 claims description 12
206010033128 Ovarian cancer Diseases 0.000 claims description 12
206010041067 Small cell lung cancer Diseases 0.000 claims description 12
238000012258 culturing Methods 0.000 claims description 12
108010074724 histone deacetylase 3 Proteins 0.000 claims description 12
208000000587 small cell lung carcinoma Diseases 0.000 claims description 12
210000000130 stem cell Anatomy 0.000 claims description 12
HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 claims description 9
229960001614 levamisole Drugs 0.000 claims description 9
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 8
230000003247 decreasing effect Effects 0.000 claims description 8
INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 claims description 8
NYPJDWWKZLNGGM-UHFFFAOYSA-N fenvalerate Chemical compound C=1C=C(Cl)C=CC=1C(C(C)C)C(=O)OC(C#N)C(C=1)=CC=CC=1OC1=CC=CC=C1 NYPJDWWKZLNGGM-UHFFFAOYSA-N 0.000 claims description 8
238000001943 fluorescence-activated cell sorting Methods 0.000 claims description 8
238000002360 preparation method Methods 0.000 claims description 8
PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 claims description 8
102000045595 Phosphoprotein Phosphatases Human genes 0.000 claims description 7
108700019535 Phosphoprotein Phosphatases Proteins 0.000 claims description 7
ZCVAOQKBXKSDMS-PVAVHDDUSA-N (+)-trans-(S)-allethrin Chemical compound CC1(C)[C@H](C=C(C)C)[C@H]1C(=O)O[C@@H]1C(C)=C(CC=C)C(=O)C1 ZCVAOQKBXKSDMS-PVAVHDDUSA-N 0.000 claims description 4
XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 4
ZVEMACCDKBQNGX-KALODSIISA-N (2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid;butanoic acid Chemical compound CCCC(O)=O.CCCC(O)=O.CCCC(O)=O.CCCC(O)=O.OC(=O)[C@@H](N)CCCN=C(N)N.OC(=O)[C@@H](N)CCCN=C(N)N.OC(=O)[C@@H](N)CCCN=C(N)N ZVEMACCDKBQNGX-KALODSIISA-N 0.000 claims description 4
JWOGUUIOCYMBPV-GMFLJSBRSA-N (3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone Chemical compound N1C(=O)[C@H](CCCCCC(=O)CC)NC(=O)[C@H]2CCCCN2C(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CC1=CN(OC)C2=CC=CC=C12 JWOGUUIOCYMBPV-GMFLJSBRSA-N 0.000 claims description 4
LLOKIGWPNVSDGJ-AFBVCZJXSA-N (3s,6s,9s,12r)-3,6-dibenzyl-9-[6-[(2s)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone Chemical compound C([C@H]1C(=O)N2CCC[C@@H]2C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N1)=O)CCCCCC(=O)[C@H]1OC1)C1=CC=CC=C1 LLOKIGWPNVSDGJ-AFBVCZJXSA-N 0.000 claims description 4
102000012438 2',3'-Cyclic-Nucleotide Phosphodiesterases Human genes 0.000 claims description 4
108010022794 2',3'-Cyclic-Nucleotide Phosphodiesterases Proteins 0.000 claims description 4
OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 claims description 4
JTDYUFSDZATMKU-UHFFFAOYSA-N 6-(1,3-dioxo-2-benzo[de]isoquinolinyl)-N-hydroxyhexanamide Chemical compound C1=CC(C(N(CCCCCC(=O)NO)C2=O)=O)=C3C2=CC=CC3=C1 JTDYUFSDZATMKU-UHFFFAOYSA-N 0.000 claims description 4
HTHGAIADRJRJOY-UHFFFAOYSA-N 6-(4-bromophenyl)-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole Chemical compound C1=CC(Br)=CC=C1C1N=C2SCCN2C1 HTHGAIADRJRJOY-UHFFFAOYSA-N 0.000 claims description 4
241001550224 Apha Species 0.000 claims description 4
WJIPXHXGFHECTD-UHFFFAOYSA-N C1=CC2=NC=CC2=C2NC(N)=NC(N)=C21 Chemical class C1=CC2=NC=CC2=C2NC(N)=NC(N)=C21 WJIPXHXGFHECTD-UHFFFAOYSA-N 0.000 claims description 4
102000004631 Calcineurin Human genes 0.000 claims description 4
108010042955 Calcineurin Proteins 0.000 claims description 4
239000005946 Cypermethrin Substances 0.000 claims description 4
239000005892 Deltamethrin Substances 0.000 claims description 4
108010002156 Depsipeptides Proteins 0.000 claims description 4
DLVJMFOLJOOWFS-UHFFFAOYSA-N Depudecin Natural products CC(O)C1OC1C=CC1C(C(O)C=C)O1 DLVJMFOLJOOWFS-UHFFFAOYSA-N 0.000 claims description 4
102000012749 Dopamine and cAMP-Regulated Phosphoprotein 32 Human genes 0.000 claims description 4
108010090047 Dopamine and cAMP-Regulated Phosphoprotein 32 Proteins 0.000 claims description 4
DIAQQISRBBDJIM-DRSCAGMXSA-N Microcystin la Chemical compound C([C@H](OC)[C@@H](C)\C=C(/C)\C=C\[C@H]1[C@@H](C(=O)N[C@H](CCC(=O)N(C)C(=C)C(=O)N[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]([C@H](C)C(=O)N[C@@H](C)C(=O)N1)C(O)=O)C(O)=O)C)C1=CC=CC=C1 DIAQQISRBBDJIM-DRSCAGMXSA-N 0.000 claims description 4
PTJGLFIIZFVFJV-UHFFFAOYSA-N N'-hydroxy-N-(3-pyridinyl)octanediamide Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CN=C1 PTJGLFIIZFVFJV-UHFFFAOYSA-N 0.000 claims description 4
102000008730 Nestin Human genes 0.000 claims description 4
108010088225 Nestin Proteins 0.000 claims description 4
JWOGUUIOCYMBPV-UHFFFAOYSA-N OT-Key 11219 Natural products N1C(=O)C(CCCCCC(=O)CC)NC(=O)C2CCCCN2C(=O)C(C(C)CC)NC(=O)C1CC1=CN(OC)C2=CC=CC=C12 JWOGUUIOCYMBPV-UHFFFAOYSA-N 0.000 claims description 4
IOUVKUPGCMBWBT-DARKYYSBSA-N Phloridzin Natural products O[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-DARKYYSBSA-N 0.000 claims description 4
102000004097 Protein phosphatase inhibitor 1 Human genes 0.000 claims description 4
108090000506 Protein phosphatase inhibitor 1 Proteins 0.000 claims description 4
RFCWHQNNCOJYTR-IRCAEPKSSA-N Tautomycin Chemical compound O([C@H]([C@H](CC1)C)[C@H](C)CC[C@H](O)[C@H](C)C(=O)C[C@@H](O)[C@@H](OC)[C@H](OC(=O)C[C@@H](O)C=2C(OC(=O)C=2C)=O)C(C)C)[C@@]21CC[C@@H](C)[C@H](CC[C@H](C)C(C)=O)O2 RFCWHQNNCOJYTR-IRCAEPKSSA-N 0.000 claims description 4
RFCWHQNNCOJYTR-UHFFFAOYSA-N Tautomycin Natural products CC=1C(=O)OC(=O)C=1C(O)CC(=O)OC(C(C)C)C(OC)C(O)CC(=O)C(C)C(O)CCC(C)C(C(CC1)C)OC21CCC(C)C(CCC(C)C(C)=O)O2 RFCWHQNNCOJYTR-UHFFFAOYSA-N 0.000 claims description 4
GXVXXETYXSPSOA-UHFFFAOYSA-N Trapoxin A Natural products C1OC1C(=O)CCCCCC(C(NC(CC=1C=CC=CC=1)C(=O)N1)=O)NC(=O)C2CCCCN2C(=O)C1CC1=CC=CC=C1 GXVXXETYXSPSOA-UHFFFAOYSA-N 0.000 claims description 4
LLOKIGWPNVSDGJ-UHFFFAOYSA-N Trapoxin B Natural products C1OC1C(=O)CCCCCC(C(NC(CC=1C=CC=CC=1)C(=O)N1)=O)NC(=O)C2CCCN2C(=O)C1CC1=CC=CC=C1 LLOKIGWPNVSDGJ-UHFFFAOYSA-N 0.000 claims description 4
ZMQRJWIYMXZORG-GZIFKOAOSA-N [(1e,3r,4r,6r,7z,9z,11e)-3,6,13-trihydroxy-3-methyl-1-[(2s)-6-oxo-2,3-dihydropyran-2-yl]trideca-1,7,9,11-tetraen-4-yl] dihydrogen phosphate Chemical compound OC/C=C/C=C\C=C/[C@H](O)C[C@@H](OP(O)(O)=O)[C@@](O)(C)\C=C\[C@@H]1CC=CC(=O)O1 ZMQRJWIYMXZORG-GZIFKOAOSA-N 0.000 claims description 4
FKAWLXNLHHIHLA-YCBIHMBMSA-N [(2r,3r,5r,7r,8s,9s)-2-[(1s,3s,4s,5r,6r,7e,9e,11e,13z)-14-cyano-3,5-dihydroxy-1-methoxy-4,6,8,9,13-pentamethyltetradeca-7,9,11,13-tetraenyl]-9-[(e)-3-[2-[(2s)-4-[[(2s,3s,4s)-4-(dimethylamino)-2,3-dihydroxy-5-methoxypentanoyl]amino]butan-2-yl]-1,3-oxazol-4 Chemical compound O1C([C@@H](C)CCNC(=O)[C@@H](O)[C@@H](O)[C@H](COC)N(C)C)=NC(\C=C\C[C@H]2[C@H]([C@H](O)C[C@]3(O2)C([C@@H](OP(O)(O)=O)[C@@H]([C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)\C=C(/C)\C(\C)=C\C=C\C(\C)=C/C#N)OC)O3)(C)C)C)=C1 FKAWLXNLHHIHLA-YCBIHMBMSA-N 0.000 claims description 4
239000002253 acid Substances 0.000 claims description 4
108010082820 apicidin Proteins 0.000 claims description 4
229930186608 apicidin Natural products 0.000 claims description 4
229960001901 bioallethrin Drugs 0.000 claims description 4
229930182747 calyculin Natural products 0.000 claims description 4
229930008399 cantharidic acid Natural products 0.000 claims description 4
UXJFDYIHRJGPFS-WPWMEQJKSA-N chembl380797 Chemical compound C=1C=CC=C(\N=C\C=2C3=CC=CC=C3C=CC=2O)C=1C(=O)NC(C)C1=CC=CC=C1 UXJFDYIHRJGPFS-WPWMEQJKSA-N 0.000 claims description 4
JIGDOBKZMULDHS-UHFFFAOYSA-N cyanogenosin-RR Natural products N1C(=O)C(CCCN=C(N)N)NC(=O)C(C)C(C(O)=O)NC(=O)C(CCCN=C(N)N)NC(=O)C(C)NC(=O)C(=C)N(C)C(=O)CCC(C(O)=O)NC(=O)C(C)C1C=CC(C)=CC(C)C(OC)CC1=CC=CC=C1 JIGDOBKZMULDHS-UHFFFAOYSA-N 0.000 claims description 4
108010073357 cyanoginosin LR Proteins 0.000 claims description 4
108010079497 cyanoginosin-LA Proteins 0.000 claims description 4
229960005424 cypermethrin Drugs 0.000 claims description 4
KAATUXNTWXVJKI-UHFFFAOYSA-N cypermethrin Chemical compound CC1(C)C(C=C(Cl)Cl)C1C(=O)OC(C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 KAATUXNTWXVJKI-UHFFFAOYSA-N 0.000 claims description 4
229960002483 decamethrin Drugs 0.000 claims description 4
OWZREIFADZCYQD-NSHGMRRFSA-N deltamethrin Chemical compound CC1(C)[C@@H](C=C(Br)Br)[C@H]1C(=O)O[C@H](C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 OWZREIFADZCYQD-NSHGMRRFSA-N 0.000 claims description 4
DLVJMFOLJOOWFS-INMLLLKOSA-N depudecin Chemical compound C[C@@H](O)[C@@H]1O[C@H]1\C=C\[C@H]1[C@H]([C@H](O)C=C)O1 DLVJMFOLJOOWFS-INMLLLKOSA-N 0.000 claims description 4
XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims description 4
235000011180 diphosphates Nutrition 0.000 claims description 4
229950010404 fostriecin Drugs 0.000 claims description 4
150000002460 imidazoles Chemical class 0.000 claims description 4
229960004125 ketoconazole Drugs 0.000 claims description 4
ZZDBMDNRQQDSKG-UHFFFAOYSA-N methyl 5-bromo-1-benzofuran-2-carboxylate Chemical compound BrC1=CC=C2OC(C(=O)OC)=CC2=C1 ZZDBMDNRQQDSKG-UHFFFAOYSA-N 0.000 claims description 4
CJIASZBWXIFQMU-LNXRSHCCSA-N microcystin LW Chemical compound C([C@H](OC)[C@@H](C)\C=C(/C)\C=C\[C@H]1[C@@H](C(=O)N[C@H](CCC(=O)N(C)C(=C)C(=O)N[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]([C@H](C)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N1)C(O)=O)C(O)=O)C)C1=CC=CC=C1 CJIASZBWXIFQMU-LNXRSHCCSA-N 0.000 claims description 4
108010004476 microcystin RR Proteins 0.000 claims description 4
JIGDOBKZMULDHS-UUHBQKJESA-N microcystin RR Chemical compound C([C@H](OC)[C@@H](C)\C=C(/C)\C=C\[C@H]1[C@@H](C(=O)N[C@H](CCC(=O)N(C)C(=C)C(=O)N[C@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H]([C@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1)C(O)=O)C(O)=O)C)C1=CC=CC=C1 JIGDOBKZMULDHS-UUHBQKJESA-N 0.000 claims description 4
JIGDOBKZMULDHS-HZJVMCKBSA-N microcystin RR Natural products CO[C@@H](Cc1ccccc1)[C@@H](C)C=C(C)C=C[C@@H]2NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](C)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](C)NC(=O)C(=C)N(C)C(=O)CC[C@@H](NC(=O)[C@H]2C)C(=O)O)C(=O)O JIGDOBKZMULDHS-HZJVMCKBSA-N 0.000 claims description 4
CYAJEMFRSQGFIG-ISWIILBPSA-N microcystin-LA Natural products CO[C@@H](Cc1ccccc1)[C@@H](C)C=C(C)C=C[C@H](NC(=O)CNC(=O)[C@@H](C)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)NC(=O)C(=C)N(C)C(=O)CC[C@@H](C)C(=O)O)C(=O)O)[C@H](C)C(=O)N CYAJEMFRSQGFIG-ISWIILBPSA-N 0.000 claims description 4
ZYZCGGRZINLQBL-GWRQVWKTSA-N microcystin-LR Chemical compound C([C@H](OC)[C@@H](C)\C=C(/C)\C=C\[C@H]1[C@@H](C(=O)N[C@H](CCC(=O)N(C)C(=C)C(=O)N[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]([C@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(O)=O)C(O)=O)C)C1=CC=CC=C1 ZYZCGGRZINLQBL-GWRQVWKTSA-N 0.000 claims description 4
DIDLWIPCWUSYPF-UHFFFAOYSA-N microcystin-LR Natural products COC(Cc1ccccc1)C(C)C=C(/C)C=CC2NC(=O)C(NC(CCCNC(=N)N)C(=O)O)NC(=O)C(C)C(NC(=O)C(NC(CC(C)C)C(=O)O)NC(=O)C(C)NC(=O)C(=C)N(C)C(=O)CCC(NC(=O)C2C)C(=O)O)C(=O)O DIDLWIPCWUSYPF-UHFFFAOYSA-N 0.000 claims description 4
108010013128 microcystin-LW Proteins 0.000 claims description 4
MEFBJEMVZONFCJ-UHFFFAOYSA-N molybdate Chemical class [O-][Mo]([O-])(=O)=O MEFBJEMVZONFCJ-UHFFFAOYSA-N 0.000 claims description 4
OYKBQNOPCSXWBL-SNAWJCMRSA-N n-hydroxy-3-[(e)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide Chemical compound ONC(=O)\C=C\C1=CC=CC(C(=O)NO)=C1 OYKBQNOPCSXWBL-SNAWJCMRSA-N 0.000 claims description 4
210000005055 nestin Anatomy 0.000 claims description 4
XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 claims description 4
229960004448 pentamidine Drugs 0.000 claims description 4
229960000490 permethrin Drugs 0.000 claims description 4
RLLPVAHGXHCWKJ-UHFFFAOYSA-N permethrin Chemical compound CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 RLLPVAHGXHCWKJ-UHFFFAOYSA-N 0.000 claims description 4
BQVCCPGCDUSGOE-UHFFFAOYSA-N phenylarsine oxide Chemical compound O=[As]C1=CC=CC=C1 BQVCCPGCDUSGOE-UHFFFAOYSA-N 0.000 claims description 4
229950009215 phenylbutanoic acid Drugs 0.000 claims description 4
IOUVKUPGCMBWBT-UHFFFAOYSA-N phloridzosid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-UHFFFAOYSA-N 0.000 claims description 4
IOUVKUPGCMBWBT-QNDFHXLGSA-N phlorizin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-QNDFHXLGSA-N 0.000 claims description 4
235000019139 phlorizin Nutrition 0.000 claims description 4
102000006241 protein phosphatase inhibitor-2 Human genes 0.000 claims description 4
108020004098 protein phosphatase inhibitor-2 Proteins 0.000 claims description 4
OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 claims description 4
LCOIAYJMPKXARU-VAWYXSNFSA-N salubrinal Chemical compound C=1C=CC2=CC=CN=C2C=1NC(=S)NC(C(Cl)(Cl)Cl)NC(=O)\C=C\C1=CC=CC=C1 LCOIAYJMPKXARU-VAWYXSNFSA-N 0.000 claims description 4
MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 claims description 4
235000013024 sodium fluoride Nutrition 0.000 claims description 4
239000011775 sodium fluoride Substances 0.000 claims description 4
YQDGWZZYGYKDLR-UZVLBLASSA-K sodium stibogluconate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].O1[C@H]([C@H](O)CO)[C@H](O2)[C@H](C([O-])=O)O[Sb]21([O-])O[Sb]1(O)(O[C@H]2C([O-])=O)O[C@H]([C@H](O)CO)[C@@H]2O1 YQDGWZZYGYKDLR-UZVLBLASSA-K 0.000 claims description 4
229960001567 sodium stibogluconate Drugs 0.000 claims description 4
FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 claims description 4
229960005314 suramin Drugs 0.000 claims description 4
229940095064 tartrate Drugs 0.000 claims description 4
150000003892 tartrate salts Chemical class 0.000 claims description 4
108010060597 trapoxin A Proteins 0.000 claims description 4
GXVXXETYXSPSOA-UFEOFEBPSA-N trapoxin A Chemical compound C([C@H]1C(=O)N2CCCC[C@@H]2C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N1)=O)CCCCCC(=O)[C@H]1OC1)C1=CC=CC=C1 GXVXXETYXSPSOA-UFEOFEBPSA-N 0.000 claims description 4
108010060596 trapoxin B Proteins 0.000 claims description 4
IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 claims description 4
LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 claims description 4
150000003681 vanadium Chemical class 0.000 claims description 4
WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims description 4
229960000237 vorinostat Drugs 0.000 claims description 4
NJOGICJCSWVJKS-MDZDMXLPSA-N 1-[11-hydroxy-2-[(e)-4-[4-hydroxy-2-[1-hydroxy-3-(3-methyl-1,7-dioxaspiro[5.5]undecan-2-yl)butyl]-3-methylidenespiro[4a,7,8,8a-tetrahydro-4h-pyrano[3,2-b]pyran-6,5'-oxolane]-2'-yl]but-3-en-2-yl]-4-methyl-1,7-dioxaspiro[5.5]undec-4-en-8-yl]propan-2-one Chemical compound O1C2(OCCCC2)CCC(C)C1C(C)CC(O)C(C(C(O)C1O2)=C)OC1CCC2(O1)CCC1\C=C\C(C)C(O1)CC(C)=CC21OC(CC(C)=O)CCC2O NJOGICJCSWVJKS-MDZDMXLPSA-N 0.000 claims description 3
229940116193 Protein phosphatase inhibitor Drugs 0.000 claims description 3
210000000133 brain stem Anatomy 0.000 claims description 3
NJOGICJCSWVJKS-UHFFFAOYSA-N norokadanone Natural products O1C2(OCCCC2)CCC(C)C1C(C)CC(O)C(C(C(O)C1O2)=C)OC1CCC2(O1)CCC1C=CC(C)C(O1)CC(C)=CC21OC(CC(C)=O)CCC2O NJOGICJCSWVJKS-UHFFFAOYSA-N 0.000 claims description 3
239000003934 phosphoprotein phosphatase inhibitor Substances 0.000 claims description 3
150000004492 retinoid derivatives Chemical class 0.000 claims description 3
230000002490 cerebral effect Effects 0.000 claims description 2
210000004289 cerebral ventricle Anatomy 0.000 claims description 2
102100039289 Glial fibrillary acidic protein Human genes 0.000 claims 2
230000004614 tumor growth Effects 0.000 abstract 1
230000014509 gene expression Effects 0.000 description 36
210000004940 nucleus Anatomy 0.000 description 36
238000011282 treatment Methods 0.000 description 32
230000000694 effects Effects 0.000 description 28
JUQMLSGOTNKJKI-UHFFFAOYSA-N 2-(4-methylpiperazin-4-ium-1-carbonyl)-7-oxabicyclo[2.2.1]heptane-3-carboxylate Chemical compound C1CN(C)CCN1C(=O)C1C(C(O)=O)C2CCC1O2 JUQMLSGOTNKJKI-UHFFFAOYSA-N 0.000 description 27
102000053171 Glial Fibrillary Acidic Human genes 0.000 description 27
108090000623 proteins and genes Proteins 0.000 description 21
230000004083 survival effect Effects 0.000 description 21
229940079593 drug Drugs 0.000 description 20
201000011510 cancer Diseases 0.000 description 18
102000004169 proteins and genes Human genes 0.000 description 18
230000005764 inhibitory process Effects 0.000 description 16
238000001262 western blot Methods 0.000 description 15
108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 14
102100031614 Ciliary neurotrophic factor Human genes 0.000 description 14
108020004414 DNA Proteins 0.000 description 14
208000003174 Brain Neoplasms Diseases 0.000 description 13
230000001086 cytosolic effect Effects 0.000 description 13
230000010261 cell growth Effects 0.000 description 12
230000017066 negative regulation of growth Effects 0.000 description 12
239000003795 chemical substances by application Substances 0.000 description 11
210000001178 neural stem cell Anatomy 0.000 description 11
108010077544 Chromatin Proteins 0.000 description 10
210000003483 chromatin Anatomy 0.000 description 10
238000000338 in vitro Methods 0.000 description 10
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
102000040945 Transcription factor Human genes 0.000 description 8
108091023040 Transcription factor Proteins 0.000 description 8
210000004556 brain Anatomy 0.000 description 8
238000005056 compaction Methods 0.000 description 8
230000002518 glial effect Effects 0.000 description 8
230000002195 synergetic effect Effects 0.000 description 8
101000741929 Caenorhabditis elegans Serine/threonine-protein phosphatase 2A catalytic subunit Proteins 0.000 description 7
102000008169 Co-Repressor Proteins Human genes 0.000 description 6
108010060434 Co-Repressor Proteins Proteins 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
108010033040 Histones Proteins 0.000 description 6
102000006947 Histones Human genes 0.000 description 6
230000009467 reduction Effects 0.000 description 6
108090000721 thyroid hormone receptors Proteins 0.000 description 6
102000004217 thyroid hormone receptors Human genes 0.000 description 6
208000008839 Kidney Neoplasms Diseases 0.000 description 5
206010038389 Renal cancer Diseases 0.000 description 5
239000013592 cell lysate Substances 0.000 description 5
201000010099 disease Diseases 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
230000036541 health Effects 0.000 description 5
201000010982 kidney cancer Diseases 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
230000003389 potentiating effect Effects 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
210000004885 white matter Anatomy 0.000 description 5
206010018338 Glioma Diseases 0.000 description 4
241000282412 Homo Species 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
230000001093 anti-cancer Effects 0.000 description 4
239000002246 antineoplastic agent Substances 0.000 description 4
210000001130 astrocyte Anatomy 0.000 description 4
230000027455 binding Effects 0.000 description 4
230000002596 correlated effect Effects 0.000 description 4
230000007423 decrease Effects 0.000 description 4
231100000673 dose–response relationship Toxicity 0.000 description 4
239000003937 drug carrier Substances 0.000 description 4
210000003527 eukaryotic cell Anatomy 0.000 description 4
206010073071 hepatocellular carcinoma Diseases 0.000 description 4
239000003276 histone deacetylase inhibitor Substances 0.000 description 4
238000003364 immunohistochemistry Methods 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
230000004807 localization Effects 0.000 description 4
239000000463 material Substances 0.000 description 4
102000005962 receptors Human genes 0.000 description 4
108020003175 receptors Proteins 0.000 description 4
238000011160 research Methods 0.000 description 4
108090000064 retinoic acid receptors Proteins 0.000 description 4
102000003702 retinoic acid receptors Human genes 0.000 description 4
230000004960 subcellular localization Effects 0.000 description 4
230000005945 translocation Effects 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
102000005569 Protein Phosphatase 1 Human genes 0.000 description 3
108010059000 Protein Phosphatase 1 Proteins 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
239000000654 additive Substances 0.000 description 3
230000000996 additive effect Effects 0.000 description 3
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
230000000259 anti-tumor effect Effects 0.000 description 3
230000003140 astrocytic effect Effects 0.000 description 3
210000005013 brain tissue Anatomy 0.000 description 3
244000309464 bull Species 0.000 description 3
238000003745 diagnosis Methods 0.000 description 3
235000014113 dietary fatty acids Nutrition 0.000 description 3
239000003623 enhancer Substances 0.000 description 3
229930195729 fatty acid Natural products 0.000 description 3
239000000194 fatty acid Substances 0.000 description 3
239000000499 gel Substances 0.000 description 3
229940121372 histone deacetylase inhibitor Drugs 0.000 description 3
SHGAZHPCJJPHSC-XFYACQKRSA-N isotretinoin Chemical compound OC(=O)/C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-XFYACQKRSA-N 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
230000030648 nucleus localization Effects 0.000 description 3
230000037361 pathway Effects 0.000 description 3
239000000047 product Substances 0.000 description 3
238000000575 proteomic method Methods 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000008107 starch Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
238000012360 testing method Methods 0.000 description 3
231100000331 toxic Toxicity 0.000 description 3
230000002588 toxic effect Effects 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
238000000539 two dimensional gel electrophoresis Methods 0.000 description 3
NIDNOXCRFUCAKQ-UMRXKNAASA-N (1s,2r,3s,4r)-bicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid Chemical compound C1[C@H]2C=C[C@@H]1[C@H](C(=O)O)[C@@H]2C(O)=O NIDNOXCRFUCAKQ-UMRXKNAASA-N 0.000 description 2
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
UHFICAKXFHFOCN-UHFFFAOYSA-N 6-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)naphthalene-2-carboxylic acid Chemical compound C1=C(C(O)=O)C=CC2=CC(C=3C=C4C(C)(C)CCC(C4=CC=3)(C)C)=CC=C21 UHFICAKXFHFOCN-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
206010003571 Astrocytoma Diseases 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 2
208000032612 Glial tumor Diseases 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
241000124079 Mylabris Species 0.000 description 2
108010026552 Proteome Proteins 0.000 description 2
230000021736 acetylation Effects 0.000 description 2
238000006640 acetylation reaction Methods 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
238000000540 analysis of variance Methods 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
238000009096 combination chemotherapy Methods 0.000 description 2
239000006071 cream Substances 0.000 description 2
230000006196 deacetylation Effects 0.000 description 2
238000003381 deacetylation reaction Methods 0.000 description 2
238000013461 design Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
150000001990 dicarboxylic acid derivatives Chemical class 0.000 description 2
230000002900 effect on cell Effects 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
230000002363 herbicidal effect Effects 0.000 description 2
239000004009 herbicide Substances 0.000 description 2
229920001477 hydrophilic polymer Polymers 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
230000003993 interaction Effects 0.000 description 2
231100000225 lethality Toxicity 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
108020001756 ligand binding domains Proteins 0.000 description 2
239000002502 liposome Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
231100000053 low toxicity Toxicity 0.000 description 2
238000004949 mass spectrometry Methods 0.000 description 2
238000005259 measurement Methods 0.000 description 2
238000001531 micro-dissection Methods 0.000 description 2
230000017095 negative regulation of cell growth Effects 0.000 description 2
230000026731 phosphorylation Effects 0.000 description 2
238000006366 phosphorylation reaction Methods 0.000 description 2
229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000002243 precursor Substances 0.000 description 2
150000004508 retinoic acid derivatives Chemical class 0.000 description 2
239000000243 solution Substances 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
239000000725 suspension Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
230000008685 targeting Effects 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
210000001635 urinary tract Anatomy 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
DJIOGHZNVKFYHH-UHFFFAOYSA-N 2-hexadecylpyridine Chemical compound CCCCCCCCCCCCCCCCC1=CC=CC=N1 DJIOGHZNVKFYHH-UHFFFAOYSA-N 0.000 description 1
KBUHKLGVLUHYJL-UHFFFAOYSA-N 4-(5,5,8,8-tetramethyl-6,7-dihydroanthracen-2-yl)benzoic acid Chemical compound C=1C=C2C=C3C(C)(C)CCC(C)(C)C3=CC2=CC=1C1=CC=C(C(O)=O)C=C1 KBUHKLGVLUHYJL-UHFFFAOYSA-N 0.000 description 1
QBEDXUHDXKEDES-SNVBAGLBSA-N 4-[(6s)-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazol-6-yl]phenol Chemical compound C1=CC(O)=CC=C1[C@@H]1N=C2SCCN2C1 QBEDXUHDXKEDES-SNVBAGLBSA-N 0.000 description 1
LKUHOPIEBQOBPT-UHFFFAOYSA-N 4-[1-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)cyclopropyl]benzoic acid Chemical compound C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1C1(C=2C=CC(=CC=2)C(O)=O)CC1 LKUHOPIEBQOBPT-UHFFFAOYSA-N 0.000 description 1
DPVGXUNWCVEIGT-UHFFFAOYSA-N 6-[2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)-1,3-dithiolan-2-yl]naphthalene-2-carboxylic acid Chemical compound C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1C1(C=2C=C3C=CC(=CC3=CC=2)C(O)=O)SCCS1 DPVGXUNWCVEIGT-UHFFFAOYSA-N 0.000 description 1
102000013563 Acid Phosphatase Human genes 0.000 description 1
108010051457 Acid Phosphatase Proteins 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
241000131283 Cantharis Species 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
CXRFDZFCGOPDTD-UHFFFAOYSA-M Cetrimide Chemical compound [Br-].CCCCCCCCCCCCCC[N+](C)(C)C CXRFDZFCGOPDTD-UHFFFAOYSA-M 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
102000002266 Dual-Specificity Phosphatases Human genes 0.000 description 1
108010000518 Dual-Specificity Phosphatases Proteins 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
239000001692 EU approved anti-caking agent Substances 0.000 description 1
101150031329 Ets1 gene Proteins 0.000 description 1
102000016359 Fibronectins Human genes 0.000 description 1
108010067306 Fibronectins Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
101000974356 Homo sapiens Nuclear receptor coactivator 3 Proteins 0.000 description 1
101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000012411 Intermediate Filament Proteins Human genes 0.000 description 1
108010061998 Intermediate Filament Proteins Proteins 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
241000623906 Lytta vesicatoria Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
101100293261 Mus musculus Naa15 gene Proteins 0.000 description 1
239000012580 N-2 Supplement Substances 0.000 description 1
101150082943 NAT1 gene Proteins 0.000 description 1
108090001146 Nuclear Receptor Coactivator 1 Proteins 0.000 description 1
108020005497 Nuclear hormone receptor Proteins 0.000 description 1
102100037223 Nuclear receptor coactivator 1 Human genes 0.000 description 1
102100022883 Nuclear receptor coactivator 3 Human genes 0.000 description 1
102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
206010035148 Plague Diseases 0.000 description 1
229920000148 Polycarbophil calcium Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
102000006478 Protein Phosphatase 2 Human genes 0.000 description 1
108010058956 Protein Phosphatase 2 Proteins 0.000 description 1
229940122454 Protein phosphatase 2A inhibitor Drugs 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
241000187747 Streptomyces Species 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
241000607479 Yersinia pestis Species 0.000 description 1
230000009471 action Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
229940009456 adriamycin Drugs 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
206010002224 anaplastic astrocytoma Diseases 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000000843 anti-fungal effect Effects 0.000 description 1
230000002583 anti-histone Effects 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
230000000573 anti-seizure effect Effects 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
229960003965 antiepileptics Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
239000003833 bile salt Substances 0.000 description 1
229940093761 bile salts Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
230000005907 cancer growth Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
RWYREGSYPCNZTL-UHFFFAOYSA-N cd564 Chemical compound C1=C(C(O)=O)C=CC2=CC(C(=O)C=3C=C4C(C)(C)CCC(C4=CC=3)(C)C)=CC=C21 RWYREGSYPCNZTL-UHFFFAOYSA-N 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
210000001638 cerebellum Anatomy 0.000 description 1
210000004720 cerebrum Anatomy 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
230000004186 co-expression Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
201000010989 colorectal carcinoma Diseases 0.000 description 1
238000011284 combination treatment Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000005956 cytoplasmic translocation Effects 0.000 description 1
230000002498 deadly effect Effects 0.000 description 1
239000002837 defoliant Substances 0.000 description 1
230000017858 demethylation Effects 0.000 description 1
238000010520 demethylation reaction Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000009547 development abnormality Effects 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
230000036267 drug metabolism Effects 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
CKSGDNACNWITHQ-UHFFFAOYSA-N endothall thioanhydride Chemical compound C1CC2C3C(=O)SC(=O)C3C1O2 CKSGDNACNWITHQ-UHFFFAOYSA-N 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
238000010195 expression analysis Methods 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
150000002191 fatty alcohols Chemical class 0.000 description 1
230000008175 fetal development Effects 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
235000013305 food Nutrition 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
230000009036 growth inhibition Effects 0.000 description 1
231100000334 hepatotoxic Toxicity 0.000 description 1
230000002962 histologic effect Effects 0.000 description 1
108091008039 hormone receptors Proteins 0.000 description 1
239000003906 humectant Substances 0.000 description 1
229920002674 hyaluronan Polymers 0.000 description 1
229960003160 hyaluronic acid Drugs 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000006882 induction of apoptosis Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
239000002917 insecticide Substances 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
230000007794 irritation Effects 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000003902 lesion Effects 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
238000011551 log transformation method Methods 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
231100001225 mammalian toxicity Toxicity 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000004530 micro-emulsion Substances 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
230000000394 mitotic effect Effects 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
239000012457 nonaqueous media Substances 0.000 description 1
102000006255 nuclear receptors Human genes 0.000 description 1
108020004017 nuclear receptors Proteins 0.000 description 1
239000002674 ointment Substances 0.000 description 1
230000008520 organization Effects 0.000 description 1
229960003104 ornithine Drugs 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
239000000575 pesticide Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
229920000768 polyamine Polymers 0.000 description 1
229950005134 polycarbophil Drugs 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
208000030266 primary brain neoplasm Diseases 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
230000026267 regulation of growth Effects 0.000 description 1
238000012827 research and development Methods 0.000 description 1
229960003471 retinol Drugs 0.000 description 1
235000020944 retinol Nutrition 0.000 description 1
239000011607 retinol Substances 0.000 description 1
238000012216 screening Methods 0.000 description 1
208000000649 small cell carcinoma Diseases 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000011255 standard chemotherapy Methods 0.000 description 1
239000003270 steroid hormone Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
230000003319 supportive effect Effects 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000011885 synergistic combination Substances 0.000 description 1
230000009044 synergistic interaction Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
229940102566 valproate Drugs 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
235000019155 vitamin A Nutrition 0.000 description 1
239000011719 vitamin A Substances 0.000 description 1
150000002266 vitamin A derivatives Chemical class 0.000 description 1
235000019154 vitamin C Nutrition 0.000 description 1
239000011718 vitamin C Substances 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
229940045997 vitamin a Drugs 0.000 description 1
239000003643 water by type Substances 0.000 description 1
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

CA002641308A 2006-02-06 2007-02-06 Utilisation de phosphatase pour traiter des tumeurs surexprimant n-cor Abandoned CA2641308A1 (fr)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US77116306P	2006-02-06	2006-02-06
US60/771,163		2006-02-06
US79720106P	2006-05-02	2006-05-02
US60/797,201		2006-05-02
PCT/US2007/003095 WO2007092414A2 (fr)	2006-02-06	2007-02-06	Utilisation de phosphatase pour traiter des tumeurs surexprimant n-cor

Publications (1)

Publication Number	Publication Date
CA2641308A1 true CA2641308A1 (fr)	2007-08-16

Family

ID=38345726

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002641308A Abandoned CA2641308A1 (fr)	2006-02-06	2007-02-06	Utilisation de phosphatase pour traiter des tumeurs surexprimant n-cor

Country Status (3)

Country	Link
EP (1)	EP1986619A4 (fr)
CA (1)	CA2641308A1 (fr)
WO (1)	WO2007092414A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2011097712A1 (fr) *	2010-02-11	2011-08-18	The Royal Institution For The Advancement Of Learning/Mcgill University	Molécule hybride à la fois agoniste du récepteur de l'acide rétinoïque et inhibitrice de l'histone désacétylase

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BRPI0806365B8 (pt)	2007-02-06	2021-05-25	Lixte Biotechnology Holdings Inc	composto, uso do composto, composição farmacêutica e uso da composição farmacêutica
WO2009020565A1 (fr) *	2007-08-03	2009-02-12	Lixte Biotechnology, Inc.	Utilisation de phosphates pour traiter des neuroblastomes et des médulloblastomes
WO2009045440A1 (fr)	2007-10-01	2009-04-09	Lixte Biotechnology Holdings, Inc.	Inhibiteurs de hdac
CA2730428A1 (fr) *	2008-08-01	2010-02-04	Lixte Biotechnology, Inc.	Procedes de regulation de la mitose cellulaire par inhibition de la phosphatase de serine/threonine
WO2010147612A1 (fr) *	2009-06-18	2010-12-23	Lixte Biotechnology, Inc.	Procédés de modulation de la régulation cellulaire par inhibition de p53
CA2877167A1 (fr)	2012-06-29	2014-01-03	Lixte Biotechnology, Inc.	Oxabicycloheptanes et oxabicycloheptenes pour le traitement du diabete
CA2909160C (fr)	2013-04-09	2021-05-25	Lixte Biotechnology, Inc.	Formulations d'oxabicycloheptanes et d'oxabicycloheptenes
CN106572989B (zh)	2014-07-24	2021-08-27	H·李·莫菲特癌症中心与研究所公司	用于治疗骨髓增生异常综合征的蛋白磷酸酶2a抑制剂
WO2016134257A1 (fr)	2015-02-19	2016-08-25	Lixter Biotechnology, Inc.	Oxabicycloheptanes et oxabicycloheptènes permettant de traiter des troubles dépressifs et de stress
CN107708686B (zh)	2015-05-15	2021-02-19	莱克斯特生物技术公司	氧杂二环庚烷前药
WO2018107004A1 (fr)	2016-12-08	2018-06-14	Lixte Biotechnology, Inc.	Oxabicycloheptanes pour la modulation de la réponse immunitaire
CN116211877B (zh) *	2022-12-30	2024-09-27	哈尔滨医科大学	根皮苷（Phlorizin）在抑制神经系统肿瘤上皮间质转化及恶性进展中的应用
CN118791500B (zh) *	2024-06-17	2025-11-21	中国药科大学	7-氧杂双环[2.2.1]庚烷-2,3-二羧酸类衍生物及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6262116B1 (en) *	1998-01-23	2001-07-17	Sloan-Kettering Institute For Cancer Research	Transcription therapy for cancers
DE10038043B4 (de) *	2000-08-02	2006-09-07	Walter, Michael, Dr.	Phamakologisch wirksame Substanz zur Behandlung kardiovaskulärer Erkrankungen
AU2001296558A1 (en) *	2000-10-03	2002-04-15	Oncopharmaceutical, Inc.	Inhibitors of angiogenesis and tumor growth for local and systemic administration
AUPR392301A0 (en) *	2001-03-23	2001-04-26	University Of Newcastle Research Associates Limited, The	Protein phosphatase inhibitors
IL149404A0 (en) *	2002-04-29	2002-11-10	Yissum Res Dev Co	METHODS AND COMPOSITIONS FOR MODULATING β-CATENIN PHOSPHORYLATION
FR2872704B1 (fr) *	2004-07-12	2007-11-02	Laurent Schwartz	Pluritherapie contre le cancer

2007
- 2007-02-06 WO PCT/US2007/003095 patent/WO2007092414A2/fr not_active Ceased
- 2007-02-06 CA CA002641308A patent/CA2641308A1/fr not_active Abandoned
- 2007-02-06 EP EP07763614A patent/EP1986619A4/fr not_active Withdrawn

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2011097712A1 (fr) *	2010-02-11	2011-08-18	The Royal Institution For The Advancement Of Learning/Mcgill University	Molécule hybride à la fois agoniste du récepteur de l'acide rétinoïque et inhibitrice de l'histone désacétylase

Also Published As

Publication number	Publication date
EP1986619A2 (fr)	2008-11-05
WO2007092414A2 (fr)	2007-08-16
WO2007092414A3 (fr)	2008-05-15
WO2007092414A8 (fr)	2008-09-04
EP1986619A4 (fr)	2010-04-28

Legal Events

Date	Code	Title	Description
2012-02-02	EEER	Examination request
2015-08-12	FZDE	Dead	Effective date: 20150617

Publication	Publication Date	Title
US20080214569A1 (en)	2008-09-04	Use of phosphatases to treat tumors overexpressing N-CoR
EP1986619A2 (fr)	2008-11-05	Utilisation de phosphatase pour traiter des tumeurs surexprimant n-cor
JP5620443B2 (ja)	2014-11-05	抗ｅｇｆｒ療法に二次的な皮疹の予防および処置のためのビタミンｋ
KR102473113B1 (ko)	2022-12-01	암 치료를 위한 병용 요법
US20090035292A1 (en)	2009-02-05	Use of phosphatases to treat neuroblastomas and medulloblastomas
CN101155577B (zh)	2015-04-22	神经纤维瘤的局部治疗
EP3258930B1 (fr)	2020-12-09	Oxabicycloheptanes et oxabicycloheptènes permettant de traiter des troubles dépressifs et de stress
US20170136053A1 (en)	2017-05-18	Novel pharmaceutical composition and uses thereof
US20180243299A1 (en)	2018-08-30	Compositions and methods for treating ewing family tumors
JP2020132625A (ja)	2020-08-31	肝臓癌に対するサフラナールとソラフェニブの併用療法
CA3238640A1 (fr)	2023-05-25	Methode de traitement du cancer par acylfulvene et rayonnement
WO2021144799A1 (fr)	2021-07-22	Cannabinoïdes destinés à être utilisés dans un traitement
Benardeau et al.	2020	The Novel Soluble Guanylyl Cyclase (sGC) Activator Runcaciguat Induced Renal Vasodilation and Reduced Kidney Damage in a Rat CKD Model: PO0600
Chen et al.	2020	Histone Deacetylase 6 Inhibition Mitigates Renal Fibrosis by Suppressing TGF-β/SMAD3 and eGFR Signaling Pathways: PO0602
Jiao et al.	2020	Crucial Role of STAT6 Signaling in Renal Fibrosis: PO0603
Mori et al.	2020	Inhibition of KIM-1-Mediated Fatty Acid Uptake by a Novel Inhibitor Attenuates Pro-Fibrotic Responses in Multiple Models of Human Primary Kidney Epithelial Cells Including Kidney Tubuloids: PO0601
Yue et al.	2024	Rational formulation of saponin and dexamethasone for the synergistic treatment of rheumatoid arthritis in vivo
AU2025267367A1 (en)	2025-12-04	Method for Treating Female Non-Smokers with Non-Small Cell Lung Cancer
US9867827B1 (en)	2018-01-16	Methods and formulations for topical treatment of psoriasis
JP2024538411A (ja)	2024-10-18	心臓保護の方法
TW202421113A (zh)	2024-06-01	用於治療肝細胞癌之包含魚針草內酯及安卓幸的組合物
US20150209364A1 (en)	2015-07-30	Method for treating epidermoid carcinoma
KR20090047501A (ko)	2009-05-12	화학요법에 의해 유발된 신경병증의 치료에 기여하는 방법 및 약학 제제
HK1175691A (en)	2013-07-12	Vitamin k for prevention and treatment of skin rash secondary to anti-egfr therapy
WO2011066545A1 (fr)	2011-06-03	Traitement de l'ostéosarcome humain

CA2641308A1 - Utilisation de phosphatase pour traiter des tumeurs surexprimant n-cor - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (5)

Publications (1)

Family

ID=38345726

Family Applications (1)

Country Status (3)

Cited By (1)

Families Citing this family (13)

Family Cites Families (6)

Cited By (1)

Also Published As

Similar Documents

Legal Events